GO:0030548 acetylcholine receptor regulator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030548 acetylcholine receptor regulator activity describes any molecular function that directly or indirectly changes the proportion of acetylcholine receptors (AChRs) in the active form.
• This activity is essential for fine-tuning cholinergic signaling at neuromuscular junctions, in the autonomic nervous system, and in the brain.
• Key proteins include nicotinic and muscarinic AChR subunits (e.g., CHRNA5, CHRM2), autoantibodies against AChRs, and intracellular modulators such as Nae1 and eNOS.
• Dysregulation of AChR regulator activity is linked to myasthenia gravis, cancer metastasis, cardiac dysfunction, and neuromuscular junction disorders.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of AChR regulatory mechanisms.
• EDITGENE provides end-to-end CRISPR services to accelerate research on acetylcholine receptor regulator activity and its disease relevance.
Description
Acetylcholine receptor regulator activity (GO:0030548) is a molecular function that encompasses any interaction with acetylcholine receptors (AChRs) that alters the proportion of receptors in their active state. This regulation is critical for controlling cholinergic neurotransmission, which underlies muscle contraction, autonomic functions, and higher cognitive processes. The term includes both direct modulation of receptor activity and indirect mechanisms that influence receptor sensitivity, trafficking, or desensitization. Researchers study this activity to understand how cholinergic signaling is fine-tuned in health and disease, and to identify therapeutic targets for disorders such as myasthenia gravis and cancer. The importance of this GO term is underscored by its involvement in neuromuscular junction development and maintenance, where precise regulation of AChRs ensures proper synaptic transmission. Moreover, recent studies have revealed that AChR regulator activity can be modulated by immune molecules, such as autoantibodies, and by intracellular signaling pathways, expanding its relevance beyond classical neurotransmission.
acetylcholine receptor regulator activity At A Glance
| GO ID | GO:0030548 |
|---|---|
| GO term | acetylcholine receptor regulator activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Modulates the proportion of active acetylcholine receptors |
| Definition | Interacting (directly or indirectly) with acetylcholine receptors such that the proportion of receptors in the active form is changed |
| Related diseases | Myasthenia gravis, intrahepatic cholangiocarcinoma, cardiac dysfunction |
| Key genes | CHRNA5, CHRM2, NAE1, NOS3, and autoantibody targets |
What Is GO:0030548?
According to QuickGO, acetylcholine receptor regulator activity (GO:0030548) is defined as interacting (directly or indirectly) with acetylcholine receptors such that the proportion of receptors in the active form is changed. This definition captures a broad range of molecular events, from ligand binding that stabilizes the active conformation to post-translational modifications that alter receptor function or localization.
Why Is acetylcholine receptor regulator activity Important in Cell Biology?
Acetylcholine receptor regulator activity is fundamental to cholinergic signaling, influencing processes ranging from muscle contraction to immune regulation. Dysregulation of this activity can lead to severe disorders, including myasthenia gravis, where autoantibodies alter AChR function, and cancer, where nicotinic receptor subunits promote metastasis. Understanding the molecular players and mechanisms of AChR regulation is therefore essential for developing targeted therapies and for interpreting experimental models of cholinergic dysfunction.
• Controls neuromuscular junction transmission and muscle function.
• Modulates autonomic nervous system output, including heart rate and glandular secretion.
• Regulates immune responses through B cell cholinergic signaling.
• Implicated in myasthenia gravis via autoantibody-mediated complement activity.
• Promotes cancer progression, such as intrahepatic cholangiocarcinoma metastasis.
• Influences cardiac myocyte signaling through muscarinic receptor nitration.
• Essential for neuromuscular junction development and maintenance.
• Target for antidepressant drug development via nicotinic partial agonists.
• Provides a basis for CRISPR-based disease modeling and drug screening.
• Helps explain heterogeneity in patient responses to cholinergic therapies.
Molecular Mechanism of acetylcholine receptor regulator activity
Direct Modulation by Ligands and Autoantibodies
In simple terms: Molecules can bind directly to acetylcholine receptors and change whether they are switched on or off.
Direct regulators include agonists, partial agonists, and antagonists that bind to AChRs and stabilize active or inactive conformations. For example, cytisine-based partial agonists modulate nicotinic AChR activity and exhibit antidepressant-like effects. Autoantibodies against AChRs can also directly alter receptor function, as seen in myasthenia gravis, where autoantibody-mediated complement activity contributes to receptor loss.
Indirect Regulation via Intracellular Signaling
In simple terms: Inside the cell, signaling pathways can modify receptors or their partners to change receptor activity.
Indirect regulation involves intracellular pathways that modify AChRs or associated proteins. For instance, muscarinic M2 receptor-induced nitration of p190A by eNOS increases RhoA activity in cardiac myocytes, illustrating how downstream signaling can modulate receptor function. Similarly, the neddylation E1 subunit Nae1 is critical for neuromuscular junction development, likely through post-translational modification of proteins that influence AChR clustering or stability.
Receptor Subunit Composition and Trafficking
In simple terms: The types of subunits that make up a receptor and how they are moved to the cell surface affect its activity.
The subunit composition of AChRs determines their functional properties and regulation. For example, the alpha5 nicotinic subunit (CHRNA5) promotes intrahepatic cholangiocarcinoma metastasis, highlighting how specific subunits can drive disease-related signaling. Regulation of receptor trafficking and clustering at the neuromuscular junction is also critical, as disruption of Nae1 leads to severe neuromuscular junction defects.
Modulation by Receptor Activity Itself
In simple terms: The activity of a receptor can feed back to regulate its own sensitivity or number.
Muscarinic acetylcholine receptor regulation can be influenced by receptor activity itself, as shown by specificity studies where receptor activation leads to changes in receptor sensitivity. This feedback regulation ensures that cholinergic signaling remains within a physiological range and can adapt to sustained stimulation.
Neurotrophic and Systemic Influences
In simple terms: Nerve-derived factors and systemic signals can change how acetylcholine receptors are regulated.
Neurotrophic relations play a role in maintaining AChR regulation, as reviewed by Gutmann, where nerve-derived factors influence receptor properties. Additionally, vagus nerve stimulation modulates distinct acetylcholine receptors on B cells, linking systemic neural activity to immune cell regulation.
Key Genes Involved in GO:0030548 acetylcholine receptor regulator activity
The following genes and proteins are key players in acetylcholine receptor regulator activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CHRNA5 | Nicotinic acetylcholine receptor subunit alpha 5 | Promotes intrahepatic cholangiocarcinoma metastasis |
| CHRM2 | Muscarinic acetylcholine receptor M2 | Induces p190A nitration and RhoA activity in cardiac myocytes |
| NAE1 | Neddylation E1 obligatory subunit | Critical for neuromuscular junction development and maintenance |
| NOS3 | Endothelial nitric oxide synthase | Mediates nitration of p190A downstream of M2 receptor |
| CHRNB1 | Nicotinic acetylcholine receptor beta 1 subunit | Component of muscle-type AChR, target of autoantibodies in myasthenia gravis |
| CHRNE | Nicotinic acetylcholine receptor epsilon subunit | Adult muscle AChR subunit, involved in neuromuscular junction function |
| RAPSN | Receptor-associated protein of the synapse | Clusters AChRs at neuromuscular junction, regulated by Nae1 pathway |
| AGRN | Agrin | Induces AChR clustering via MuSK-LRP4 pathway |
| MUSK | Muscle-specific kinase | Essential for neuromuscular junction formation and AChR clustering |
| LRP4 | LDL receptor-related protein 4 | Co-receptor for agrin, required for AChR clustering |
| DOK7 | Docking protein 7 | Adaptor protein in MuSK signaling, regulates AChR clustering |
| CHAT | Choline acetyltransferase | Synthesizes acetylcholine, indirectly affects receptor regulation |
| ACHE | Acetylcholinesterase | Degrades acetylcholine, influences receptor activation |
| CHRNA1 | Nicotinic acetylcholine receptor alpha 1 subunit | Autoantibody target in myasthenia gravis |
| CHRNB2 | Nicotinic acetylcholine receptor beta 2 subunit | Involved in brain nicotinic signaling and antidepressant effects |
| CHRNA4 | Nicotinic acetylcholine receptor alpha 4 subunit | Forms high-affinity nicotinic receptors in brain |
| CHRM1 | Muscarinic acetylcholine receptor M1 | Mediates cholinergic effects in autonomic and CNS |
How Is acetylcholine receptor regulator activity Regulated?
Acetylcholine receptor regulator activity is regulated at multiple levels. Receptor activity itself can modulate sensitivity, as shown for muscarinic receptors. Intracellular signaling pathways, such as neddylation via Nae1, are essential for neuromuscular junction development and maintenance, indicating that post-translational modifications regulate AChR clustering and function. Additionally, neurotrophic factors influence AChR properties, and systemic neural activity, such as vagus nerve stimulation, can modulate AChR expression on immune cells. These layers of regulation ensure precise control of cholinergic signaling.
acetylcholine receptor regulator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHRNA5 | Intrahepatic cholangiocarcinoma metastasis | Knockout or overexpression in cholangiocarcinoma cell lines |
| CHRM2 | Cardiac dysfunction | Point mutation or knockout in cardiomyocytes |
| NAE1 | Neuromuscular junction disorders | Conditional knockout in mouse motor neurons |
| CHRNA1 | Myasthenia gravis | Knock-in of autoantibody-targeted epitopes |
| CHRNB2 | Depression | Overexpression or knockout in mouse brain |
Myasthenia Gravis
Myasthenia gravis is an autoimmune disorder characterized by autoantibodies against acetylcholine receptors, leading to receptor loss and muscle weakness. Heterogeneity in autoantibody-mediated complement activity contributes to disease variability. Understanding AChR regulator activity is crucial for developing targeted therapies.
Cancer Metastasis
The alpha5 nicotinic acetylcholine receptor subunit (CHRNA5) promotes intrahepatic cholangiocarcinoma metastasis, linking AChR regulator activity to cancer progression. This suggests that modulating AChR function could be a therapeutic strategy in cholangiocarcinoma.
Cardiac Dysfunction
Muscarinic M2 receptor-induced nitration of p190A by eNOS increases RhoA activity in cardiac myocytes, implicating AChR regulator activity in cardiac signaling and potential dysfunction. This pathway may contribute to heart failure or arrhythmias.
Neuromuscular Junction Disorders
Disruption of Nae1, a key regulator of neddylation, leads to severe neuromuscular junction defects, highlighting the importance of AChR regulator activity in neuromuscular development and maintenance. This has implications for congenital myasthenic syndromes.
From acetylcholine receptor regulator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CHRNA5 promote metastasis? | Knockout or overexpression in cancer cell lines |
| How does Nae1 regulate neuromuscular junction? | Conditional knockout in mice |
| What is the role of M2 receptor nitration in cardiac myocytes? | Point mutation of p190A nitration sites |
| How do autoantibodies affect AChR function? | Knock-in of human AChR subunits in mice |
| Can nicotinic partial agonists treat depression? | Overexpression of CHRNB2 in mouse brain |
| How does vagus nerve stimulation affect B cells? | Knockout of specific AChR subunits in immune cells |
How to Study the acetylcholine receptor regulator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for AChR regulation | Identify novel regulators |
| Patch-clamp electrophysiology | Ion channel activity | Measure AChR function |
| Live-cell imaging | Receptor localization and clustering | Study neuromuscular junction formation |
| Mass spectrometry | Post-translational modifications | Detect nitration or neddylation |
| ELISA | Autoantibody levels | Diagnose myasthenia gravis |
| RNA-seq | Gene expression changes | Assess transcriptional regulation |
| Western blot | Protein expression and modification | Validate knockout or knock-in |
| Behavioral assays | Depression-like behaviors | Test nicotinic partial agonists |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify genes that regulate AChR activity, such as those affecting receptor clustering or signaling. These screens are powerful for discovering novel regulators and potential drug targets.
Electrophysiology and Imaging
Patch-clamp electrophysiology and live-cell imaging measure AChR activity and localization in real time. These methods are used to assess the impact of mutations or drugs on receptor function.
Proteomics and Post-translational Modification Analysis
Mass spectrometry-based proteomics can identify post-translational modifications, such as nitration or neddylation, that regulate AChR function. This helps elucidate indirect regulatory mechanisms.
Autoantibody Assays
Cell-based assays and ELISA measure autoantibody-mediated complement activity against AChRs, providing insights into myasthenia gravis heterogeneity.
How CRISPR Can Be Used to Study GO:0030548 acetylcholine receptor regulator activity
Knockout
CRISPR knockout of genes such as CHRNA5 or NAE1 can reveal their roles in AChR regulation and disease. For example, Nae1 knockout in mice disrupts neuromuscular junction development, and CHRNA5 knockout reduces metastasis in cholangiocarcinoma models.
Point Mutation
Introducing point mutations in AChR subunits or regulatory proteins can dissect specific phosphorylation or nitration sites. For instance, mutating p190A nitration sites can test their role in M2 receptor signaling.
Knock-in
Knock-in of human AChR subunits or autoantibody epitopes into mouse models can mimic human myasthenia gravis and test autoantibody effects. This approach helps study species-specific regulation.
Overexpression
Overexpression of CHRNA5 or CHRNB2 can drive cancer metastasis or modulate depression-like behaviors, respectively. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports acetylcholine receptor regulator activity Research
Researchers studying acetylcholine receptor regulator activity-related genes often need to determine whether a candidate gene is causally involved in receptor regulation or disease. EDITGENE provides comprehensive CRISPR services to enable such investigations with precision and efficiency.
Contact EDITGENE today to design your custom CRISPR model for acetylcholine receptor regulator activity research.
Frequently Asked Questions About acetylcholine receptor regulator activity
What is acetylcholine receptor regulator activity?
It is a molecular function (GO:0030548) that changes the proportion of acetylcholine receptors in the active form by direct or indirect interaction.
What genes are involved in acetylcholine receptor regulator activity?
Key genes include CHRNA5, CHRM2, NAE1, NOS3, and various AChR subunits such as CHRNA1 and CHRNB2.
How is acetylcholine receptor regulator activity studied?
Researchers use CRISPR knockout screens, electrophysiology, imaging, proteomics, and autoantibody assays.
What diseases are linked to acetylcholine receptor regulator activity?
Myasthenia gravis, intrahepatic cholangiocarcinoma, cardiac dysfunction, and neuromuscular junction disorders.
What is the role of CHRNA5 in cancer?
CHRNA5 promotes intrahepatic cholangiocarcinoma metastasis, making it a potential therapeutic target.
How does Nae1 affect neuromuscular junctions?
Nae1 is critical for neuromuscular junction development and maintenance, likely through neddylation of key proteins.
Can acetylcholine receptor regulator activity be targeted for depression?
Yes, nicotinic partial agonists like cytisine show antidepressant-like effects by modulating AChR activity.
What is the connection between vagus nerve stimulation and AChR regulation?
Vagus nerve stimulation modulates distinct acetylcholine receptors on B cells, limiting germinal center responses.
How do autoantibodies affect acetylcholine receptors in myasthenia gravis?
Autoantibodies against AChRs mediate complement activity and contribute to receptor loss and disease heterogeneity.
What CRISPR models are available for studying AChR regulation?
Knockout, point mutation, knock-in, and overexpression models can be generated for genes like CHRNA5, CHRM2, and NAE1.
Conclusion
Acetylcholine receptor regulator activity (GO:0030548) is a critical molecular function that fine-tunes cholinergic signaling in health and disease. Its dysregulation contributes to myasthenia gravis, cancer metastasis, cardiac dysfunction, and neuromuscular disorders. Understanding the genes and mechanisms involved provides opportunities for therapeutic intervention. EDITGENE offers comprehensive CRISPR services to support research on this important regulatory activity.
References
- 1. Fu Y et al.. 2024. Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis.. Signal Transduct Target Ther 9(1):63 PMID: 38453934
- 2. Obaid AH et al.. 2022. Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis.. Neurol Neuroimmunol Neuroinflamm 9(4) PMID: 35473886
- 3. Levay MK et al.. 2023. The Muscarinic Acetylcholine M(2) Receptor-Induced Nitration of p190A by eNOS Increases RhoA Activity in Cardiac Myocytes.. Cells 12(20) PMID: 37887276
- 4. Gutmann E. 1976. Neurotrophic relations.. Annu Rev Physiol 38:177-216 PMID: 769654
- 5. Siman RG et al.. 1981. Specificity of muscarinic acetylcholine receptor regulation by receptor activity.. J Neurochem 37(5):1099-108 PMID: 7299390
- 6. Jing H et al.. 2025. Neddylation E1 Obligatory Subunit Nae1 Is Critical to Neuromuscular Junction Development and Maintenance.. J Neurosci 45(33) PMID: 40659529
- 7. Mineur YS et al.. 2009. Cytisine-based nicotinic partial agonists as novel antidepressant compounds.. J Pharmacol Exp Ther 329(1):377-86 PMID: 19164465
- 8. Kurata-Sato I et al.. 2024. Vagus nerve stimulation modulates distinct acetylcholine receptors on B cells and limits the germinal center response.. Sci Adv 10(17):eadn3760 PMID: 38669336
